JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kubicka, S.
Right arrow Articles by Trautwein, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kubicka, S.
Right arrow Articles by Trautwein, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 45, 32137-32144, November 5, 1999


p53 Represses CAAT Enhancer-binding Protein (C/EBP)-dependent Transcription of the Albumin Gene
A MOLECULAR MECHANISM INVOLVED IN VIRAL LIVER INFECTION WITH IMPLICATIONS FOR HEPATOCARCINOGENESIS*

Stefan KubickaDagger , Florian Kühnel, Lars Zender, Karl Lenhard Rudolph, Jörg Plümpe, Michael Manns, and Christian Trautwein

From the Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, 30625 Hannover, Germany

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p53 is a transcription factor that is activated by genotoxic stress and mediates cell cycle arrest and apoptosis. Here we demonstrate that infection of mouse liver with recombinant E1/E3-deleted adenovirus leads to p53 activation and simultaneously to the down-regulation of albumin gene expression. In vitro transcription assays indicate that transcriptional mechanisms mediated through the albumin promoter are responsible for reduced albumin mRNA levels during viral infection. Albumin expression is maintained in the liver by a combination of liver-enriched transcription factors such as CAAT enhancer-binding protein (C/EBP)alpha and C/EBPbeta . We show that p53 wild type and tumor-derived p53 mutations repress C/EBP-mediated transactivation of the albumin promoter. The binding of C/EBPalpha or -beta to its cognate sequence in the albumin promoter is not inhibited by p53 expression. Deletion analysis and domain swapping experiments show that repression of C/EBPbeta -mediated transactivation is dependent on the N-terminal domain of p53 and the transactivation domain, leucine zipper domain, and the inhibitory domain II (amino acids 163-191) of C/EBPbeta . Our results provide a molecular explanation for the p53-mediated down-regulation of liver-specific gene expression after viral infection. Additionally, as overexpression of p53 mutants is frequently found in undifferentiated hepatocellular carcinomas, the same mechanisms may contribute to the lack of liver-specific gene transcription in these tumors.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

As a "guardian of the genome," p53 mediates cell cycle arrest and subsequently DNA repair or apoptosis, depending on the cellular environment and the degree of cellular damage (for review, see Refs. 1 and 2). Compared with other tumor suppressor genes, p53 has an unusual spectrum of mutations in human tumors. Most of the p53 gene alterations are missense mutations, which occur in the DNA-binding domain of one p53 allele associated with a deletion of the second allele (3, 4). The spectrum of p53 gene mutations and the observation that most of the p53 missense mutations are usually strongly overexpressed in human tumors indicate a positive selection rather than a loss during carcinogenesis. Several studies show that the introduction of specific p53 mutations into tumor cells with p53 deletions in both alleles confer increased growth rate, tumorigenicity, metastatic potential, and resistance to chemotherapy (5-10).

The p53 gene appears to be a frequent target for mutations in hepatocellular carcinomas from high risk areas, whereas the average frequency of p53 missense mutations in hepatocellular carcinomas from low risk areas is only 10-30% (11, 12). The p53 alterations in hepatocellular carcinomas from high incidence areas are preferentially G to T substitutions at the third nucleotide pair of codon 249 (13). Experimental and epidemiological data indicate that aflatoxin B1 exposure results in mutations at p53 codon 249 (14, 15). Another mechanism for inactivating the function of p53 in hepatitis B associated hepatocellular carcinomas is the binding of p53 wild type by the viral protein HBx and the blockage of p53 entry into the nucleus. As a consequence liver tumors developed without evidence of p53 mutations in a HBx transgenic mouse model (16). Although p53 wild type function was impaired by HBx binding, in some animals a small proportion of cells in advanced tumors acquired p53 mutations, which suggests that p53 missense mutations harbor a selection advantage in hepatocarcinogenesis and may contribute to tumor progression.

Actually, it has been shown in several studies that in human hepatocellular carcinomas p53 mutations are closely related to the progression and the dedifferentiation of the tumors (17-20). Furthermore, it has been demonstrated that ectopic expression of the hepatocellular carcinoma hot spot mutation 249S leads to increased survival and mitotic activity of p53 -/- human hepatoma cells (8) and transgene expression in a p53 knock-out mouse results in an enhanced number of hepatocytes in the G1 phase of the cell cycle (9).

Liver-specific gene transcription in differentiated hepatocytes is controlled by a combination of cell type-specific transcription factors. One group is the C/EBP1 family of transcription factors, which are considered as proteins maintaining cell differentiation (for review, see Ref. 21). They are expressed at late stage during embryonic liver development and in contrast to other liver-specific transcription factors, the amount of C/EBP proteins in hepatoma cell lines is reduced to approximately 10% compared with untransformed hepatocytes (22, 23).

The tumor suppressor Rb positively controls terminal adipocyte differentiation by binding and activating C/EBP proteins (24). In contrast, wild type p53 inhibits the C/EBPbeta -mediated gene transcription (25, 26). It was recently suspected that p53 wild type decreases sequence-specific DNA binding of C/EBP transcription factors due to protein-protein interaction (27). However, the influence of p53 wild type or hepatocellular carcinoma-derived p53 mutations on liver-specific gene transcription is still unknown.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Lines and Plasmids-- The human hepatoma cell lines HepG2, Huh7 and Hep3B and 293T cells were obtained from the American Type Culture Collection. The Hep3B cell line was maintained in minimal essential medium (Life Technologies, Inc.) supplemented with antibiotics, L-glutamine, sodium pyruvate, and 10% heat-inactivated fetal calf serum (Life Technologies, Inc.). The 293T, HepG2, and Huh7 cell lines were grown in Dulbecco's modified Eagle's medium supplemented with antibiotics, L-glutamine, sodium pyruvate, and 10% heat-inactivated fetal calf serum (Life Technologies, Inc.). The cells were grown in 5% CO2 at 37 °C.

The plasmids used for transfection were CMV promoter-driven expression vectors and a CAT-reporter plasmid. The reporter plasmid contained 400 bp of the human albumin promotor (pAlbumin-CAT) upstream of the chloramphenicol acetyltransferase gene as described before (28, 29). The coding sequences of the p53 and the C/EBPbeta expression vectors are indicated in Fig. 1. The human C/EBPalpha and C/EBPbeta wild type and the albumin expression vectors have been described previously (30-32). A pCMV-beta gal vector (CMVbeta ; CLONTECH) was used as an internal standard and was cotransfected in each experiment. The CMV-p53wt expression vector (pC53SN3) was generously provided by B. Vogelstein. The expression vectors for the tumor-derived p53 missense mutations Tyr-220 right-arrow Cys, Arg-249 right-arrow Met, and Arg-249 right-arrow Ser were obtained by polymerase chain reaction mutagenesis as described before (33). The plasmids for the expression of p53 deletions were kindly provided by S. Deb (p53del1-59, p53del393-327; Ref. 34) and M. Oren (p53N315, p53DDelta SS; Ref. 35). The expression plasmid p53-22Q/23S was kindly provided by A. Levine (36). Expression vectors for the C/EBPbeta deletions (pCRP2Delta 116-149, pCRP2Delta 163-191) and the C/EBPbeta chimeric proteins (pMexCRP2-1-47(VP16), pMexCRP2-GCN4) were kindly provided by P. Johnson (31). The adenoviral vector Ad5-CMVlacZ was kindly provided by D. Brenner (37).


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 1.   Schematic representation of the p53- and C/EBPbeta -derived proteins encoded by the expression vectors used in this study. The number indicate the amino acid position of wild type proteins, assuming that the proteins are initiated at the first in frame AUG. The p53 mutations N315 and DDelta SS are derived from the mouse p53 cDNA, whereas all other p53- and C/EBPbeta -mutations are derivates from the corresponding human wild type proteins. Dotted white box, deletions; shaded gray box, evolutionary conserved regions of p53. AD, transactivation domain of C/EBPbeta ; B, basic DNA binding region of C/EBPbeta ; LZ, leucine zipper domain of C/EBPbeta .

Transfection Experiments and CAT Assays-- Hepatoma cells (HepG2, Hep3B and Huh7) and 293T cells were grown on 60-mm dishes to 60% confluence when used for transfection experiments. Hepatoma cell lines were transfected using the calcium phosphate precipitation method and an overnight incubation at 3% CO2 and 35 °C. Transient transfection of 293T cells were performed as described (38). The amount of reporter and expression vectors used in the experiments, is indicated in the figure legends. The total DNA concentration was kept constant in each transfection experiment by adding pBSK+ (Stratagene) to a final amount of 6 µg of DNA/dish. All transfection mixtures for CAT assay analysis contained 0.5 µg of the beta -galactosidase expression plasmid CMV-beta -gal (CLONTECH) as an internal standard for transfection efficacy. CAT assays were performed 48 h after transfection using thin layer chromatography for the separation of the reaction products. CAT assays were quantified by using a Fuji Imager and normalized to transfection efficacies by beta -galactosidase assays. All transfection experiments were repeated at least three times.

Nuclear Extracts, in Vitro Transcription and Translation of C/EBPbeta , and Electrophoretic Mobility Shift Assays (EMSA)-- Nuclear extracts were isolated from mouse liver as described by Lichtsteiner et al. (39) or from hepatoma cell lines (HepG2, Hep3B) transiently cotransfected with 3 µg of the p53 expression vectors and 3 µg of the C/EBPalpha or C/EBPbeta expression vectors, using the Dignam C method as described before (30).

For in vitro translation of C/EBPbeta , the pet vectors system was used as described earlier (40). The cDNA was subcloned into a bacterial expression vector and transformed into E. coli strain BL21/DE-3/pLys S. The protein was induced and purified as described before (40). Nuclear extracts from 293T cells were prepared by the Dignam C method after transfection with 6 µg of the p53 expression vectors.

EMSA experiments were performed using nuclear extracts or in vitro translated protein as indicated and 1 ng of end-labeled DNA. The D-site of the human albumin promoter served as the cognate DNA binding sequence for C/EBPalpha and C/EBPbeta in electrophoretic mobility shift assays (41). For determining the sequence-specific DNA binding capacity of p53, the consensus site of p53 was used (5'-GGGCATGTCCGGGCAT-3'). The oligonucleotides were purchased from Eurogentec (Seraing, Belgium) and used as 32P-labeled probes.

Binding buffer consisted of 25 mM HEPES (pH7, 6), 5 mM MgCl2, 34 mM KCl, 2 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 1 µg of poly(dI-dC)/µl, and 2 µg of bovine serum albumin/µl. The binding reaction was incubated for 30 min on ice and subsequently separated in a 6% polyacrylamide gel. Electrophoresis was carried out for 4 h at 300 V. After electrophoresis, the gel was dried and exposed for autoradiography.

SDS-Polyacrylamide Gel Electrophoresis and Western Blot Analysis-- Protein concentrations of nuclear extracts were measured by Bio-Rad Microassay (Bio-Rad, Munich, Germany). 10 µg of nuclear extracts were separated on a 10% SDS-polyacrylamide gel and blotted onto Hybond N membrane (Millipore, Frankfurt, Germany). As primary antibodies we used p53 pAb240 (Dianova, Hamburg), C/EBPalpha 14AA (Santa Cruz Biotechnology, Santa Cruz, CA), and a polyclonal C/EBPbeta antibody as described before (30). The antigen-antibody complexes were visualized using the ECL detection system as recommended by the manufacturer (Amersham Pharmacia Biotech, Braunschweig, Germany).

Northern Blot Analysis-- Northern blot analysis was performed according to standard procedures. Total RNA was isolated with the Qiagen RNeasy kit (Qiagen) according to the manufacturer's instructions. 15 µg of total RNA was analyzed through a 1% agarose formaldehyde gel, followed by transfer to Hybond N membranes (Amersham Pharmacia Biotech). The albumin, C/EBPalpha , C/EBPbeta , and beta -actin cDNA probes were labeled with [alpha -32P]ATP according to random priming (Roche Molecular Biochemicals, Mannheim, Germany).

In Vitro Transcription Assay-- In vitro transcription assays were performed as described by Gorski et al. (42). As DNA templates we used the G-less cassette-containing constructs Alb 400 and AdML 200 G-free, which were a generous gift from U. Schibler. Nuclear extracts were isolated from rat liver by the method described by Lichtsteiner et al. (39). Nuclear extracts and template DNA were preincubated on ice for 15 min in a total volume of 17 µl. 3 µl of the reaction mix containing 20× NTP, RNasin, and 10 µCi of [32P]UTP were added. The transcription was performed for 45 min at 30 °C. The reaction was terminated by adding the stop buffer (250 mM NaCl, 20 mM Tris/HCl, pH 7, 5, 5 mM EDTA, 1% SDS), 2 µl of 10 mg/ml tRNA, and 4 µl of 10 mg/ml proteinase K solution. After phenol/chloroform extraction and ethanol precipitation, the RNAs were separated on a 8% polyacrylamide/urea gel, visualized by autoradiography, and quantified by Fuji phosphoimager.

Adenoviral Vector, in Vivo Infection of Mouse and Rat Liver-- To exclude immunological elimination of infected hepatocytes, we used nude mice and nude rats for our experiments. Female NMRI-nu/nu mice and female NZNU-nu/nu rats were obtained from the Zentrales Tierlaboratorium (Hannover Medical School, Hannover, Germany).

The recombinant, replication-deficient adenoviral vector Ad5-CMV-lacZ was prepared, purified, and titered as described previously (37). Ad5-CMV-lacZ is an adenovirus type 5-based, E1/E3-deleted vector, containing the CMV promoter-driven E. coli lacZ gene (coding for the beta -gal protein) (37). The recombinant adenovirus was stored in a buffer solution of 10% glycerol, 10 mM Tris/HCl, pH 7,4, and 1 mM MgCl2. In vivo adenoviral infection was carried out by the administration of Ad vector into the tail vein of nude mice or rats at a concentration of 1 × 109 plaque-forming units/g. Mice and rats were injected with 0,3 ml of a solution obtained by dialysis against 10 mM Tris-HCl, pH 8,0, 1 mM MgCl2, 140 mM NaCl at 4 °C. To evaluate the efficacy of Ad vectors infecting the hepatocytes in vivo, liver specimen of mice and rats were frozen on dry ice and subsequently frozen sections were stained with beta -gal substrate X-gal (5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Viral Infection of the Liver Is Associated with an Increase in p53 Expression and Repression of Albumin Gene Transcription-- Viral infection of the liver triggers mechanisms in hepatocytes that are either directly related to the virus or a consequence of an immune response directed against viral epitopes. To exclude mechanisms related to the immune system, we used nude mice and nude rats for our experiments. In vivo infection of mouse and rat liver with recombinant adenovirus was performed by administration of 0.3 ml of a solution containing 1 × 109 plaque-forming units/g into the tail vein. X-gal staining of a specimen of the liver demonstrated that approximately 80-100% of the hepatocytes are infected with viral particles (Fig. 2A).


View larger version (53K):
[in this window]
[in a new window]
  		Fig. 2.   A, staining of mouse liver with X-gal, 24 h after infection with recombinant adenovirus Ad5-CMV-Lacz. Approximately 80-100% of the hepatocytes are infected with the adenovirus and express the beta -gal marker gene. B, response of mouse liver after adenoviral infection. Nuclear extracts and total RNA were isolated from mouse livers 8 and 24 h after adenoviral infection. As a control (C), mice were used which were injected with 0.3 ml of the dialyzed puffer without adenoviral particles. Northern and Western blot analysis demonstrate the down-regulation of albumin mRNA, although the protein and the mRNA levels of the transcription factors C/EBPalpha and -beta remain constant. Concurrent with the albumin mRNA down-regulation p53 protein is up-regulated. Gel shift experiments reveal the that the sequence-specific DNA binding of p53 is activated after adenoviral infection. Specific p53/DNA complex formation (black arrow) is confirmed by supershift with p53 antibody pAb421 (Dianova) (white arrow). Positive controls (P) for p53 and C/EBPalpha and -beta Western blots were obtained by isolation of nuclear extracts of 293T cells, 48 h after a transient transfection with 6 µg of p53 and C/EBPalpha and -beta expression vectors. C, transcriptional activity of the albumin promoter after adenoviral infection. In vitro transcription assays were performed with nuclear extracts, isolated at the time point 48 h after tail vein injection of rats. The construct containing adenovirus major late promoter (AdML 200) linked to a G-less cassette of 200 bp was used as a control (C) and added in all incubation mixes with the construct containing the albumin promoter (Alb 400) linked to a G-less cassette of 400 bp.

Mice were sacrificed 8 and 24 h after viral infection, and the livers were harvested for isolation of nuclear extracts and total RNA. Northern blot analysis demonstrated a significant down-regulation of albumin mRNA expression 8 and 24 h after viral infection (Fig. 2B). In contrast, the mRNA and protein levels of the liver-enriched transcription factors C/EBPalpha and C/EBPbeta remained constant. As virus infection may induce genotoxic stress, p53 expression was studied. An increase in nuclear p53 expression was found, which was associated with down-regulation of albumin mRNA levels (Fig. 2B). Using gel shift experiments, an increase in p53 sequence-specific DNA binding was evident 8 and 24 h after virus infection (Fig. 2B).

To assess whether the decrease of albumin mRNA expression level was transcriptionally mediated through the albumin promoter, in vitro transcription analysis was performed. Albumin-specific transcription was measured using a construct where the albumin promoter was combined with a G-less cassette of 400 bp (Fig. 2C). As an internal control, the adenovirus major late promoter was included. Fig. 2C shows that 48 h after adenoviral infection of rat liver the transcriptional activity of the albumin promoter was reduced to approximately 17%, while transcription of the AdML promoter was unaffected. Therefore, these experiments indicate that transcriptional mechanisms mediated through the promoter reduce albumin mRNA levels after adenoviral transduction.

p53 Modulates C/EBPbeta -dependent Transactivation of the Albumin Promoter-- p53 wild type represses the activity of a variety of promoters by complex formation with TBP and with other transcription factors. Furthermore, p53 wild type specifically inhibits C/EBPbeta -mediated transactivation (25, 26). Our in vivo results show that down-regulation of albumin gene transcription was associated with p53 overexpression. Therefore, we were interested to study the role of wild type and mutant p53 for the transcriptional control of the albumin promoter.

Binding of liver-specific transcription factors to the B- and D-site in the albumin promoter confers high transcription of the gene in differentiated hepatocytes, while this regulation is impaired in hepatoma cells. By cotransfecting expression vectors for either C/EBPalpha or -beta with an albumin promoter construct, higher transcription can be reconstituted in hepatoma cells, as shown in Figs. 3 and 4. Three hepatoma cell lines with different p53 status were included in this study. HepG2 cells express wild type p53 and Huh7 cells overexpress the p53-220C mutation, while in Hep3B cells the p53 gene is deleted. Cotransfection experiments were performed in all cell lines with an albumin reporter plasmid and expression vectors for C/EBPbeta and p53wt. Additionally, the hepatocellular carcinoma-derived p53 mutations p53-249M, p53-249S, and p53-220C, which are unable to transactivate p53-responsive genes (33), were included.


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 3.   A, effect of p53 wild type and hepatocellular carcinoma-derived p53 mutations on the C/EBPbeta transactivation of the human albumin promoter. Three hepatoma cell lines were used with different p53 backgrounds: Hep3B (p53: deleted/deleted), HepG2 (p53: wt/wt), and Huh7 (p53: deleted/220C). Hepatoma cells were plated in 60-mm dishes and transfected with 6 µg of DNA after 24 h, using the calcium phosphate method. All proteins were expressed under the transcriptional control of the CMV immediate early promoter/enhancer. Amounts of expression vectors used are indicated. CAT assays were performed 48 h after transfection. The CAT activity obtained with the C/EBPbeta -induced albumin-CAT in the absence of p53 expression vectors was set to 100%. The results shown represent the mean of three independent experiments. B, dose-dependent effect of p53 wild type and p53-249S on transcription of the albumin promoter. Hep3B cells were used for these experiments, which lack any intrinsic p53 expression. Cells were plated in 60-mm dishes and transfected with 6 µg of DNA after 24 h, using the calcium phosphate method. Amounts of expression vectors used are indicated. Albumin promoter activity was stimulated in all experiments by cotransfecting 0.5 µg of C/EBPbeta expression vector. CAT assays were performed 48 h after transfection.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 4.   A, effect of p53 wild type and various p53 mutations on C/EBPalpha and -beta activation of the albumin promoter. All cotransfection experiments were performed in Hep3B cells. The amounts of expression vectors used are indicated. 2 µg of reporter plasmids and 2 µg of CMVbeta gal expression vectors were used in all experiments. The CAT activity found when an expression vector for C/EBPalpha or -beta was transfected with albumin-CAT alone was set to 100%. The results shown represent the mean of three independent experiments. B, nuclear expression of the p53, C/EBPbeta , and C/EBPalpha . Nuclear extracts were isolated from Hep3B cells cotransfected with equal amounts of p53- and C/EBP-expression vectors (3 µg). 10 µg of nuclear protein were resolved on a denaturing 10% polyacrylamide gel and electroblotted onto Hybond N membrane. p53 and C/EBP proteins were detected with the primary antibodies p53 pAb240 (Dianova), C/EBPalpha 14AA (Santa Cruz Biotechnology), and a polyclonal C/EBPbeta antibody (30).

Cotransfection of wild type p53 represses C/EBP-dependent activation of the albumin promoter in a dose-dependent manner (Fig. 3, A and B). However, for p53 mutations, this effect was only evident in HepG2 and Hep3B cells, but not in the Huh7 cells, which implicates that the transcriptional repression through the intrinsic p53-220C mutation cannot be further enhanced by additional ectopic tumor-derived p53 mutations (Fig. 3A).

The Transactivation Domain of p53 Is Essential to Repress C/EBPalpha - and -beta -dependent Target Gene Transcription-- Activation of target genes is an essential mechanism of wild type p53 to act as a tumor suppressor (43). Tumor-derived p53 mutations are mostly located in the DNA binding domain (3, 4), whereas other domains of the molecule are less frequently mutated. Therefore, in further experiments, we examined which p53 domains are involved in repression of C/EBP-dependent activation of the albumin promoter. These studies were performed in Hep3B cells where the intrinsic p53 gene is deleted on both alleles.

The albumin reporter construct was cotransfected with different p53 mutants. Because there is evidence that the N-terminal transactivation domain and the C-terminal regulatory domain of p53, which mediates tetramerization of p53, are involved in positive and negative regulation of gene transcription, mutations in the transactivation domain (p53-22/23, p53del59), which are unable to transactivate p53-responsive genes and a deletion of the regulatory C-terminal domain (p53-del327), were included into the study. Since it has been shown that C-terminal fragments of p53 can inhibit the transactivation domain of heterologous transcription factors (35), two truncated (mouse) p53 proteins (p53-N315 and p53-DDelta SS) were also used in the experiments (Fig. 1).

The transactivation of the albumin promoter by C/EBPalpha and -beta was only repressed by p53wt, by the tumor-derived p53 mutations, and, to a lesser degree, by the C-terminal p53 deletion p53del393-327 (Fig. 4A). The expression of the double point mutation 22/23 and the C-terminal fragment DDelta SS had no effect on the C/EBP-mediated transactivation. The results showed that only p53 mutants with a wild type transactivation domain repress C/EBP-mediated transactivation of the albumin promoter.

To exclude a direct role of the p53 constructs on the expression of C/EBPalpha and -beta , Western blot analysis with nuclear extracts was performed (Fig. 4B). No change in nuclear expression of C/EBP proteins was evident when the different p53 mutants were cotransfected.

p53 Wild Type and Tumor-derived p53 Mutations Have No Impact on Sequence-specific DNA Binding of C/EBPalpha or -beta -- We performed gel shift analysis, using the D-site of the albumin promoter, to determine whether sequence-specific DNA binding of C/EBP isoforms is altered by p53 expression and thus represses transcription of the albumin promoter.

Nuclear extracts derived from Hep3B cells cotransfected with C/EBPalpha or -beta and p53 mutants were incubated with a 32P-labeled oligonucleotide, representing the D-site of the albumin promoter. These studies revealed that neither p53wt nor the different p53 mutations used in this analysis alter DNA binding of C/EBPalpha (Fig. 5A) or C/EBPbeta (data not shown).


View larger version (71K):
[in this window]
[in a new window]
  		Fig. 5.   p53 does not influence DNA binding of C/EBPalpha and C/EBPbeta . C/EBPalpha - and C/EBPbeta -specific complexes in the EMSA were identified as retarded bands, which supershifted in the presence of specific antibodies (black arrow). A, EMSA were performed with nuclear extracts (2 µg of protein) of Hep3B cells cotransfected with 3 µg of C/EBPalpha and 3 µg of p53 expression vectors. B, EMSA were performed using nuclear extracts (1 µg of protein) of 293T cells transfected with 6 µg of p53 expression vectors together with 1 ng of in vitro translated C/EBPbeta .

To further sensitize our analysis, recombinant C/EBPbeta was incubated with nuclear extracts of 293T cells, transfected with high amounts of p53 expression vectors. 293T cells were used, because of very high transfection efficacy (>70% compared with 5-10% in Hep3B cells). Also, these studies clearly showed that p53 does not inhibit DNA binding of C/EBPbeta (Fig. 5B), indicating that a different mechanism is relevant to explain repression of C/EBP-dependent gene transcription through p53.

Repression of C/EBPbeta -dependent Gene Transcription through p53 Requires the Inhibitory Domain II, the Transactivation, and the Leucine Zipper Domain of C/EBPbeta -- We investigated whether specific C/EBPbeta domains are involved in the repression mediated by p53. Besides the DNA binding, transactivation, and leucine zipper domain of C/EBPbeta , two inhibitory regions were characterized (31). Therefore, four different constructs, in which all the functional domains (except the DNA binding) of C/EBPbeta were replaced or deleted, were used. In the constructs C/EBPbeta Delta 116-149 and Delta 163-191, the inhibitory domain I and II were deleted, respectively. In the C/EBPbeta /VP16 construct, the transactivation domain of C/EBPbeta was replaced by the one of VP16 and in the C/EBPbeta -GCN4 construct the leucine zipper was swapped by the one of GCN4. Each C/EBPbeta mutant was cotransfected with the albumin reporter gene and the different p53 mutant constructs in Hep3B cells (Fig. 6).


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 6.   Distinct regions of C/EBPbeta are essential to mediate p53-dependent repression of the albumin promoter. The diagrams of the C/EBPbeta -derived transcription factors used in these cotransfection experiments were shown in Fig. 1. Cotransfection experiments and CAT assays were performed in Hep3B cells as described in legend to Fig. 3.

In Fig. 6 (A and B), the results of the C/EBPbeta Delta 116-149 and Delta 163-191 are depicted. C/EBPbeta Delta 116-149 showed the same repression of the albumin promoter transactivation through p53 as C/EBPbeta wild type (Fig. 6A). In contrast, differences were found with the C/EBPbeta Delta 169-193 construct where the inhibitory region is deleted which modulates DNA binding (31). Albumin promoter transactivation through C/EBPbeta Delta 163-191 is not repressed by p53-220C, -249M, and -249S; also, p53 wild type revealed a 2-fold reduced transcriptional repression compared with the experiments with C/EBPbeta wild type (Fig. 6B).

These results showed that the inhibitory domain II, which modulates DNA binding, but not the inhibitory domain I, which modulates transactivation, is required for the repressive effect mediated by p53, although C/EBP binding to DNA is not altered by p53. However, the molecular function of the inhibitory domain II in p53-dependent transcriptional repression remains unknown.

In Fig. 6 (C and D), the mutants C/EBPbeta /VP16 and C/EBPbeta -GCN4 were studied. Both constructs showed results similar to those found with the C/EBPbeta Delta 163-191 deletion. Transactivation of the albumin promoter was not repressed through tumor-derived p53 mutations, only the p53-del 327 and p53wt decreased the transcriptional activity to 50% (Fig. 6, C and D). Therefore, our results indicate that wild type or mutant p53 repress C/EBP-dependent transcription of the albumin promoter through the leucine zipper, the inhibitory domain II, and the transactivation domain of C/EBPbeta .

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

After adenoviral infection of the liver, p53 expression and DNA binding increased, which was associated with a decrease in albumin gene transcription mediated through the albumin promoter. Interestingly, protein and mRNA levels of C/EBPalpha and -beta remained constant during the time course of the virally induced stress response. Thus we hypothesized that p53 could be involved in the down-regulation of albumin promoter activity. Reporter gene analysis demonstrated that p53 is directly involved in repressing C/EBP-dependent activation of albumin gene transcription. These results implicate that p53 mediates down-regulation of liver-specific gene transcription during stress response induced by nonimmunological mechanisms after viral infection of the liver. Thus, our study gives a molecular explanation for the phenomenon that liver-specific gene expression decreases during acute viral hepatitis although liver cell mass remained unchanged. Obviously, a different situation is evident during hepatocarcinogenesis. In the course of tumor development and tumor progression, tissue-specific gene transcription decreases. Therefore, it was also the aim of this study to investigate the role of p53 mutations on liver-specific gene transcription.

p53 is a strong transcriptional repressor. Complex formation of the general transcription factor TBP with wild type p53, but not with tumor-derived p53 mutations, results in repression of TATA box-mediated transcription (44, 45). Additionally, interaction of wild type p53 with a set of transcription factors has been shown, which may lead to TATA box-unrelated repression of gene transcription (46, 47). The property of mutants to alter gene transcription in a manner distinct from wild type p53, is thought to mediate the specific gain of function phenotype of some p53 mutations (5, 48-51). The impact of a particular p53 mutation on the transcriptional regulation may be cell type-dependent and as a consequence may determine, at least in part, the tumor-specific spectrum of p53 missense mutations.

The role of C/EBP proteins for cell proliferation has been studied before. Overexpression of either C/EBPalpha or beta  in liver cells blocks cell proliferation (52, 53). Additionally hepatocytes derived from C/EBPalpha -/- mice have a higher rate of DNA synthesis and immortalization (54). Therefore, C/EBP proteins, which contribute to cell differentiation, seem an attractive target of repression during neoplastic transformation. Li et al. (55) reported that transcriptional repression might contribute to neoplastic growth. More specifically it has been demonstrated that the repression of gene transcription is necessary for neoplastic transformation by c-Myc (56). Since c-Myc down-regulates genes by inhibiting the function of C/EBP transcription factors, a link between cell transformation and repression of C/EBP-mediated gene transcription is strongly suggested (57).

No uniform pattern has been reported for different p53 mutants in controlling C/EBP-dependent gene transcription in hepatoma cells. The p53 mutation Val-143 right-arrow Ala has been described to repress C/EBPbeta -mediated transactivation, whereas Cys-135 right-arrow Val and Lys-132 right-arrow Phe enhance the transcriptional activity of C/EBPbeta in hepatoma cells (26). In our study we show that the hepatocellular carcinoma-derived mutations p53-220C, -249M, and -249S retain a capacity to repress C/EBPalpha - and -beta -mediated transactivation of the human albumin promoter in hepatoma cells, which can be considered to be a factor that determines the selection during hepatocarcinogenesis. Besides the tumor-derived mutations, only p53 proteins with a wild type transactivation domain are capable to repress C/EBP-mediated gene transcription. These results are consistent with other studies, which demonstrated that the N-terminal domain of p53 is involved in transcriptional repression (58). Additionally, our experiments demonstrate that the C-terminal domain of p53 is not generally required for p53-dependent gene repression as suggested by others (35, 59). Although it has been shown that C-terminal fragments of p53 can inhibit the transactivation domain of some transcription factors (35), we did not find any significant repression of C/EBP-dependent gene transcription through p53-N315 and p53-DDelta SS.

In further experiments we investigated the molecular mechanisms which are required to repress C/EBPbeta -dependent gene transcription. Western blot and gel shift experiments clearly demonstrated that p53 did not change the expression of C/EBP proteins and the affinity toward its cognate DNA. These results are in contrast to a study by Webster et al. (27) using the C/EBP binding site of the insulin promoter. They showed that wild type p53 expression reduces DNA binding of C/EBP proteins.

Our results further demonstrate that the transcriptional repression through tumor-derived p53 mutations is dependent on the C/EBPbeta transactivation domain, the inhibitory domain II (amino acids 163-191), and the leucine zipper domain of C/EBPbeta . Since wild type p53 is also a general repressor of TATA box-containing promoters (44, 45), this mechanism might additionally account for the wild type p53-mediated repression of the albumin promoter. Although it remains unknown how p53 represses C/EBP-mediated gene transactivation, it is obvious that this modulation is specifically dependent on the p53 transactivation domain and on several C/EBPbeta domains. Furthermore, the C/EBPbeta domains, which are found to be necessary for transcriptional repression by p53 mutations, are essential in modulating the cell type-specific activity of C/EBPbeta (31). Therefore, further experiments seem promising to test our hypothesis that the same C/EBPbeta domains required for hepatocyte differentiation are involved in the repression through p53 and this mechanism may thus contribute to hepatocarcinogenesis.

In summary, we show an increase of p53 expression after adenoviral infection, which is associated with a down-regulation of promoter-dependent transcription of the albumin gene. We demonstrate that different regions of C/EBP and p53 are involved in this regulation despite the lack of sequence-specific DNA binding of p53 to the albumin promoter. Transcriptional repression of C/EBP-mediated transactivation through p53 wild type might contribute to the down-regulation of liver-specific gene expression during liver failure. Since overexpression of p53 mutations is associated with dedifferentiation of human hepatocellular carcinomas, this mechanism may also contribute to the selection of p53 mutants during hepatocarcinogenesis.

    ACKNOWLEDGEMENTS

We thank B. Vogelstein for providing the p53 expression vector pC53SN3. We thank A. Levine for providing the expression vector p53-22Q/23S. We thank P. Johnson for the generous gift of the expression plasmids pCRP2Delta 116-149, pCRP2Delta 163-191, pMexCRP2-1-47(VP16), and pMexCRP2-GCN4. We thank S. Deb for providing the plasmids p53del1-59 and p53del393-327. We thank M. Oren for providing the plasmids p53N315 and p53DDelta SS. We thank D. Brenner for providing the adenoviral vector Ad5CMVlacZ.

    FOOTNOTES

* This work was supported by Deutsche Forschungsgemeinschaft (DFG) Sonderforschungsbereich 265 Projekt C4A and DFG Grant TR 285 3-4.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This paper is dedicated to Prof. Dr. Dr. Dr. h. c. K-.H. Meyer zum Büschenfelde on the occasion of his 70th birthday.

Dagger To whom correspondence should be addressed: Dept. of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Carl Neubergstr. 1, 30625 Hannover, Germany. Fax: 49-511-532-4896; E-mail: kubicka.stefan@mh-hannover.de.

    ABBREVIATIONS

The abbreviations used are: C/EBP, CAAT enhancer-binding protein; beta -gal, beta -galactosidase; CMV, cytomegalovirus; CAT, chloramphenicol acetyltransferase; bp, base pair(s); EMSA, electrophoretic mobility shift assay; X-gal, 5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Selivanova, G., and Wiman, K. G. (1995) Adv. Cancer Res. 66, 143-180[Medline] [Order article via Infotrieve]
2. Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, O. B., and Stark, G. R. (1998) J. Biol. Chem. 273, 1-4[Free Full Text]
3. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994) Cancer Res. 54, 4855-4878[Free Full Text]
4. Hussain, S. P., and Harris, C. C. (1998) Cancer Res. 58, 4023-4037[Free Full Text]
5. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. (1993) Nat. Genet. 4, 42-46[CrossRef][Medline] [Order article via Infotrieve]
6. Sun, Y., Nakamura, K., Wedel, E., and Colburn, N. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2827-2831[Abstract/Free Full Text]
7. Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P., Yeargin, J., and Haas, M. (1994) Am. J. Pathol. 145, 702-714[Abstract]
8. Ponchel, F., Puisieux, A., Tabone, E., Michot, J. P., Fröschl, G., Morel, A. P., Frebourg, T., Fontaniere, B., Oberhammer, F., and Ozturk, M. (1994) Cancer Res. 54, 2064-2068[Abstract/Free Full Text]
9. Yin, L., Ghebranious, N., Chakraborty, S., Sheehan, C. E., Ilic, Z., and Sell, S. (1998) Hepatology 27, 73-80[CrossRef][Medline] [Order article via Infotrieve]
10. Blandino, G., Levine, A. J., and Oren, M. (1999) Oncogene 18, 477-485[CrossRef][Medline] [Order article via Infotrieve]
11. Unsal, H., Yakicier, C., Marcais, C., Kew, M., Volkmann, M., Zentgraf, H., Isselbacher, K. J., and Ozturk, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 822-826[Abstract/Free Full Text]
12. Kubicka, S., Trautwein, C., Schrem, H., Tillman, H., and Manns, M. P. (1995) J. Hepatol. 23, 412-419[CrossRef][Medline] [Order article via Infotrieve]
13. Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., and Harris, C. C. (1991) Nature 350, 427-428[CrossRef][Medline] [Order article via Infotrieve]
14. Aguilar, F., Hussain, S. P., and Cerutti, P. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8586-8590[Abstract/Free Full Text]
15. Ozturk, M. (1991) Lancet 338, 1356-1359[CrossRef][Medline] [Order article via Infotrieve]
16. Ueda, H., Ullrich, S. J., Gangemi, J. D., Kappel, C. A., Ngo, L., Feitelson, M. A., and Jay, G. (1995) Nat. Genet. 9, 41-47[CrossRef][Medline] [Order article via Infotrieve]
17. Oda, T., Tsuda, H., Scarpa, A., Sakamoto, M., and Hirohashi, S. (1992) Cancer Res. 52, 6358-6364[Abstract/Free Full Text]
18. Tanaka, S., Toh, Y., Adachi, E., Matsumata, T., Mori, R., and Sugimachi, K. (1993) Cancer Res. 53, 2884-2887[Abstract/Free Full Text]
19. Teramoto, T., Satonaka, K., Kitazawa, S., Fujimori, T., Kozaburo, H., and Maeda, S. (1994) Cancer Res. 54, 231-235[Abstract/Free Full Text]
20. Hayashi, H., Sugio, K., Matsumata, T., Adachi, E., Takenaka, K., and Sugimachi, K. (1995) Hepatology 22, 1702-1707[CrossRef][Medline] [Order article via Infotrieve]
21. Wedel, A., and Ziegler-Heitbrock, H. W. (1995) Immunobiology 193, 171-185[Medline] [Order article via Infotrieve]
22. Mischoulon, D., Rana, B., Bucher, N. L., and Farmer, S. R. (1992) Mol. Cell. Biol. 12, 2553-2560[Abstract/Free Full Text]
23. Levrat, F., Vallet, V., Berbar, T., Miquerol, L., Kahn, A., and Antoine, B. (1993) Exp. Cell Res. 209, 307-316[CrossRef][Medline] [Order article via Infotrieve]
24. Chen, P. L., Riley, D. J., Chen-Kiang, S., and Lee, W. H. (1996) Proc. Natl. Acad. Sci. 93, 465-469[Abstract/Free Full Text]
25. Margulies, L., and Sehgal, P. B. (1993) J. Biol. Chem. 268, 15096-15100[Abstract/Free Full Text]
26. Wang, L., Rayanade, R. J., Garcia, D., Patel, K., Pan, H., and Sehgal, P. B. (1995) J. Biol. Chem. 270, 23159-23165[Abstract/Free Full Text]
27. Webster, N. J. G., Resnik, J. L., Reichart, D. B., Strauss, B., Haas, M., and Seely, B. L. (1996) Cancer Res. 56, 2781-2788[Abstract/Free Full Text]
28. Pietrangelo, A., Panduro, A., Roy-Chowdhury, J., and Shafritz, D. A. (1992) J. Clin. Invest. 89, 1755-1760
29. Morris, G. F., Bischoff, J. R., and Mathews, M. B. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 895-899[Abstract/Free Full Text]
30. Trautwein, C., Caelles, C., van der Geer, P., Hunter, T., Karin, M., and Chojkier, M. (1993) Nature 364, 544-547[CrossRef][Medline] [Order article via Infotrieve]
31. Williams, C. W., Baer, M., Dillner, A. J., and Johnson, P. F. (1995) EMBO J. 14, 3170-3183[Medline] [Order article via Infotrieve]
32. Trautwein, C., Rakemann, T., Pietrangelo, A., Plumpe, J., Montosi, G., and Manns, M. P. (1996) J. Biol. Chem. 271, 22262-22270[Abstract/Free Full Text]
33. Kubicka, S., Trautwein, C., Niehof, M., and Manns, M. P. (1997) Hepatology 25, 867-873[CrossRef][Medline] [Order article via Infotrieve]
34. Subler, M. A., Martin, D. W., and Deb, S. (1994) Oncogene 9, 1351-1359[Medline] [Order article via Infotrieve]
35. Shaulian, E., Haviv, I., Shaul, Y., and Oren, M. (1995) Oncogene 10, 671-680[Medline] [Order article via Infotrieve]
36. Lin, J., Teresky, A. K., and Levine, A. J. (1995) Oncogene 10, 2387-2390[Medline] [Order article via Infotrieve]
37. Bradham, C. A., Qian, T., Streetz, K., Trautwein, C., Brenner, D. A., and Lemasters, J. J. (1998) Mol. Cell. Biol. 18, 6353-6364[Abstract/Free Full Text]
38. Graham, F. L., and van der Eb, A. J. (1973) Virology 54, 536-539[CrossRef][Medline] [Order article via Infotrieve]
39. Lichtsteiner, S., Wuarin, J., and Schibler, U. (1987) Cell 51, 963-973[CrossRef][Medline] [Order article via Infotrieve]
40. Trautwein, C., van der Geer, P., Karin, M., Hunter, T., and Chojkier, M. (1994) J. Clin. Invest. 93, 2554-2561
41. Poll, V., Mancini, F. P., and Cortese, R. (1990) Cell 63, 643-653[CrossRef][Medline] [Order article via Infotrieve]
42. Gorski, K., Carneiro, M., and Schiebler, U. (1986) Cell 47, 767-776[CrossRef][Medline] [Order article via Infotrieve]
43. Pietenpol, J. A., Tokino, T., Thiagalingam, S., el-Deiry, W. S., Kinzler, K. W., and Vogelstein, B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1998-2002[Abstract/Free Full Text]
44. Mack, D. H., Vartikar, J., Pipas, J. M., and Laimins, L. A. (1993) Nature 363, 281-283[CrossRef][Medline] [Order article via Infotrieve]
45. Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M., and Aloni, Y. (1993) Oncogene 8, 1183-1193[Medline] [Order article via Infotrieve]
46. Iotsova, V., Crepieux, P., Montpellier, C., Laudet, V., and Stehelin, D. (1996) Oncogene 13, 2331-2337[Medline] [Order article via Infotrieve]
47. Dugimont, T., Montpellier, C., Adriaenssens, E., Lottin, S., Dumont, L., Iotsova, V., Lagrou, C., Stehelin, D., Coll, J., and Curgy, J. J. (1998) Oncogene 16, 2395-2401[CrossRef][Medline] [Order article via Infotrieve]
48. Chin, K. V., Ueda, K., Pastan, I., and Gottesman, M. M. (1992) Science 255, 459-462[Abstract/Free Full Text]
49. Deb, S., Jackson, C. T., Subler, M. A., and Martin, D. W. (1992) J. Virol. 66, 6164-6170[Abstract/Free Full Text]
50. Shiio, Y., Yamamoto, T., and Yamaguchi, N. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5206-5210[Abstract/Free Full Text]
51. Ueba, T., Tosaka, T., Takahashi, J. A., Shibata, F., Florkiewicz, R. Z., Vogelstein, B., Oda, Y., Kikuchi, H., and Hatanaka, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9009-9013[Abstract/Free Full Text]
52. Buck, M., Turler, H., and Chojkier, M. (1994) EMBO J. 13, 851-860[Medline] [Order article via Infotrieve]
53. Watkins, P. J., Condreay, J. P., Huber, B. E., Jakobs, S. J., and Adams, D. J. (1996) Cancer Res. 56, 1063-1067[Abstract/Free Full Text]
54. Soriano, H. E., Kang, D. C., Finegold, M. J., Hicks, M. J., Wang, N. D., Harrision, W., and Darlington, G. J. (1998) Hepatology 27, 392-401[CrossRef][Medline] [Order article via Infotrieve]
55. Li, J., Thurm, H., Chang, H. W., Iacovoni, J., and Vogt, P. K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10885-10888[Abstract/Free Full Text]
56. Lee, L. A., Dolde, C., Barrett, J., Wu, C. S., and Dang, C. V. (1996) J. Clin. Invest. 97, 1687-1695[Medline] [Order article via Infotrieve]
57. Mink, S., Mutschler, B., Weiskirchen, R., Bister, K., and Klempnauer, K. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6635-6640[Abstract/Free Full Text]
58. Liu, X., Miller, C. W., Koeffler, P. H., and Berk, A. J. (1993) Mol. Cell. Biol. 13, 3291-3300[Abstract/Free Full Text]
59. Sang, B. C., Chen, J. Y., Minna, J., and Barbosa, M. S. (1994) Oncogene 9, 853-859[Medline] [Order article via Infotrieve]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
T. Schneider-Merck, Y. Pohnke, R. Kempf, M. Christian, J. J. Brosens, and B. Gellersen
P